StockLearn from Clustermicro · Stock Breakout ScannerStockLearn
← US stocks and world indices

Gilead Sciences (GILD)

US-listed stock · Healthcare · Biotechnology · close 17 Nov 2026
Close
$170.26
Day change
+1.6%
1 month
+9.0%
6 months
+31.4%
1 year
+37.2%
3 years
+125.7%
5 years
+152.4%
From 52-week high
-2.4%
Weinstein stage
Stage 2
advancing
Gilead Sciences closed at $170.26 on 17 Nov 2026. Over the past year it has gained 37.2%, and over five years +152% in all (+20.3% a year). It is 2.4% below its 52-week closing high of $174.48, set on 4 Nov 2026, and 43.9% above its 52-week closing low of $118.30. The price is above its 200-day average of $141.99 - an average that is itself still rising. On Stan Weinstein's stage analysis it is in Stage 2: advancing - above a rising 150-day average. Its deepest fall from a peak in the period shown was 29%. It made a loss over the last twelve months reported (to 30 Sep 2026), so it has no P/E. On revenue of $31.0B (+6.5% on a year earlier), the net margin was -12.5%.

Valuation and profitability

Market value
$213.0B
P/E (TTM)
loss
Price / book
16.3
Net margin
-12.5%
Return on equity
-29.6%
Revenue growth
+6.5%
Net income growth
to a loss

From the company's SEC filings: the last twelve months to 30 Sep 2026, built from its 10-K and 10-Q reports. P/E and market value use the 17 Nov 2026 close, with the latest quarter's diluted share count; P/E is market value over net income, which stays right through a stock split. Growth compares with the twelve months a year earlier.

Price, RSI and MACD

Price · +30.3% over the period
118133148163178May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
RSI (14) · 61.8
305070
MACD (12, 26, 9) · histogram -0.40
-3-0.71.646.3
Price · +37.2% over the period
109126143161178Nov 25Jan 26Mar 26May 26Jul 26Sep 26Nov 26
RSI (14) · 61.8
305070
MACD (12, 26, 9) · histogram -0.40
-4-12.15.18.1
Price · +83.8% over the period
6997125153180Nov 24Mar 25Jul 25Nov 25Mar 26Jul 26Nov 26
RSI (14) · 61.8
305070
MACD (12, 26, 9) · histogram -0.40
-3.9-0.92.15.18.1
Price · +127.2% over the period
5787117147177Nov 23Apr 24Sep 24Feb 25Jul 25Dec 25May 26Oct 26
RSI (14) · 61.8
305070
MACD (12, 26, 9) · histogram -0.40
-4-12.15.18.1
Price · +152.9% over the period
5183116149181Aug 22May 23Feb 24Nov 24Aug 25May 26
RSI (14) · 61.8
305070
MACD (12, 26, 9) · histogram -0.40
-3.9-124.97.9
Price: daily close adjusted for stock splits, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

50-day average $155.90 · 200-day average $141.99 · 52-week closing range $118.30 – $174.48

Other Healthcare stocks

NameClose1M1Y5YP/EStage
Merck$143.37-1.8%+54.4%+73.6%144.82
Johnson & Johnson$278.70+9.1%+39.6%+70.7%42.42
Eli Lilly$1,415.55+12.6%+38.5%+442.0%45.92
Regeneron Pharmaceuticals$957.76+21.1%+36.0%+49.2%21.02
Amgen$457.93+5.9%+34.0%+122.5%26.62
Elevance Health$433.93+1.3%+31.1%+1.0%18.42
Bristol Myers Squibb$61.35+2.7%+31.1%+3.2%13.62
McKesson$1,091.67+8.6%+27.6%+387.7%27.12
AbbVie$292.82+2.6%+25.1%+149.5%50.22
Vertex Pharmaceuticals$534.20+6.9%+23.1%+183.8%34.32
UnitedHealth$389.68-2.9%+21.6%-13.2%22.12
Thermo Fisher$686.79-0.5%+21.1%+7.8%36.02
Pfizer$28.47-3.8%+13.5%-44.0%40.62
CVS Health$85.81-7.1%+9.4%-7.5%10.03
Medtronic$102.32+8.0%+6.3%-13.2%25.12
HCA Healthcare$501.19+9.2%+5.0%+105.5%16.11
Danaher Corporation$225.77-1.4%+2.4%-17.8%36.82
Stryker Corporation$317.54+7.8%-11.8%+21.2%33.71
Abbott Laboratories$104.71-0.2%-19.5%-18.6%38.72
Intuitive Surgical$430.53+0.9%-21.3%+19.1%51.21

← All US stocks and world indices · NSE stocks

Daily closes to 17 Nov 2026, adjusted for stock splits (not dividends), from Google Finance and Yahoo Finance. US stock prices in US dollars; index levels in points. Figures may be delayed and are for information only.
For research & education only — not investment advice or a recommendation to buy or sell any security. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by any exchange or index provider. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.